Microemulsion and poloxamer microemulsion-based gel for sustained transdermal delivery of diclofenac epolamine using in-skin drug depot: In vitro/in vivo evaluation

被引:86
作者
Fouad, Shahinaze A. [1 ]
Basalious, Emad B. [2 ]
El-Nabarawi, Mohamed A. [2 ]
Tayel, Saadia A. [2 ]
机构
[1] Ahram Canadian Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[2] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo 11562, Egypt
关键词
Diclofenac epolamine; In-skin depot; Sustained transdermal delivery; D-optimal design; Microemulsion; D-OPTIMAL DESIGN; OPTIMIZATION; FORMULATION; SYSTEMS; ACECLOFENAC; PERMEATION; ABSORPTION; RELEASE; SODIUM; OIL;
D O I
10.1016/j.ijpharm.2013.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Microemulsion (ME) and poloxamer microemulsion-based gel (PMBG) were developed and optimized to enhance transport of diclofenac epolamine (DE) into the skin forming in-skin drug depot for sustained transdermal delivery of drug. D-optimal mixture experimental design was applied to optimize ME that contains maximum amount of oil, minimum globule size and optimum drug solubility. Three formulation variables; the oil phase X-1 (Capryol (R)), Smix X-2 (a mixture of Labrasol (R)/Transcutol (R), 1:2 w/w) and water X-3 were included in the design. The systems were assessed for drug solubility, globule size and light absorbance. Following optimization, the values of formulation components (X1, X2, and X3) were 30%, 50% and 20%, respectively. The optimized ME and PMBG were assessed for pH, drug content, skin irritation, stability studies and ex vivo transport in rat skin. Contrary to PMBG and Flector (R) gel, the optimized ME showed the highest cumulative amount of DE permeated after 8 h and the in vivo anti-inflammatory efficacy in rat paw edema was sustained to 12 h after removal of ME applied to the skin confirming the formation of in-skin drug depot. Our results proposed that topical ME formulation, containing higher fraction of oil solubilized drug, could be promising for sustained transdermal delivery of drug. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:569 / 578
页数:10
相关论文
共 30 条
[1]   Nanocarrier for the Transdermal Delivery of an Antiparkinsonian Drug [J].
Azeem, Adnan ;
Ahmad, Farhan J. ;
Khar, Roop K. ;
Talegaonkar, Sushama .
AAPS PHARMSCITECH, 2009, 10 (04) :1093-1103
[2]   Microemulsion-Based Gel of Terbinafine for the Treatment of Onychomycosis: Optimization of Formulation Using D-Optimal Design [J].
Barot, Bhavesh S. ;
Parejiya, Punit B. ;
Patel, Hetal K. ;
Gohel, Mukesh C. ;
Shelat, Pragna K. .
AAPS PHARMSCITECH, 2012, 13 (01) :184-192
[3]   SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: Development and optimization [J].
Basalious, Emad B. ;
Shawky, Nevine ;
Badr-Eldin, Shaimaa M. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 391 (1-2) :203-211
[4]  
BINKS BP, 1989, PROG COLL POL SCI S, V79, P208
[5]   Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions [J].
Chang, JY ;
Oh, YK ;
Choi, HG ;
Kim, YB ;
Kim, CK .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 241 (01) :155-163
[6]   Microemulsion-based hydrogel formulation of ibuprofen for topical delivery [J].
Chen, Huabing ;
Chang, Xueling ;
Du, Danrong ;
Li, Jin ;
Xu, Huibi ;
Yang, Xiangliang .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 315 (1-2) :52-58
[7]  
Conte A, 2002, DRUG EXP CLIN RES, V28, P249
[8]   Application of a mixture experimental design in the optimization of a self-emulsifying formulation with a high drug load [J].
Gao, P ;
Witt, MJ ;
Haskell, RJ ;
Zamora, KM ;
Shifflett, JR .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2004, 9 (03) :301-309
[9]   Optimization of self-microemulsifying drug delivery systems (SMEDDS) using a D-optimal design and the desirability function [J].
Holm, R. ;
Jensen, I. H. M. ;
Sonnergaard, J. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (09) :1025-1032
[10]   Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology [J].
Huang, YB ;
Tsai, YH ;
Lee, SH ;
Chang, JS ;
Wu, PC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 289 (1-2) :87-95